Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
Ixchel Lima-PosadaMatthieu SoulieYohan StephanRoberto Palacios RamirezBenjamin BonnardLionel NicolBertram PittPeter KolkhofPaul MulderFrédéric JaisserPublished in: Journal of the American Heart Association (2024)
We showed that the nonsteroidal mineralocorticoid receptor antagonist finerenone reduces renal hypertrophy and albuminuria, attenuates cardiac diastolic dysfunction and cardiac fibrosis, and improves cardiac perfusion in a preclinical nondiabetic CKD model.